Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Omaha, Nebraska 68198


RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Vaccine therapy may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy following chemotherapy and peripheral stem cell transplantation in treating patients who have non-Hodgkin's lymphoma.

Study summary:

OBJECTIVES: - Determine the humoral and cellular immune responses in patients with follicular non-Hodgkin's lymphoma treated with autologous lymphoma-derived idiotype vaccine with keyhole limpet hemocyanin plus sargramostim (GM-CSF). - Determine the safety and toxicity of this regimen in these patients in the post-transplant setting. - Determine the changes in quantitative bcl-2 in the blood and bone marrow of these patients before and at various times after the series of idiotype vaccines. OUTLINE: Vaccinations begin at day 100 or up to 6 months after hematopoietic stem cell transplantation. Patients receive autologous lymphoma-derived idiotype vaccine plus keyhole limpet hemocyanin subcutaneously (SC) on day 1. Sargramostim (GM-CSF) SC is administered on days 1-4. Treatment repeats every 4 weeks for 4 doses, followed 12 weeks later by the fifth and final dose. Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically proven grade I, II, or III follicular non-Hodgkin's lymphoma that failed induction therapy - Previously received no more than 2 high-dose chemotherapies before hematopoietic stem cell transplantation - Minimal disease state at day 100 to 6 months post-transplantation - Lymph nodes smaller than 2 centimeters (cm) - Less than 20% bone marrow involvement with lymphoma - Uncertain complete remission, defined by greater than 75% reduction in the size of the pre-transplantation mass not representing active disease - Tissue sample safely accessible by biopsy, needle aspiration, or phlebotomy - Must have adequate circulating lymphoma cells PATIENT CHARACTERISTICS: Age: - Over 19 Performance status: - Karnofsky greater than 70% Life expectancy: - Not specified Hematopoietic: - See Disease Characteristics - Absolute neutrophil count greater than 1,000/mm^3* - CD4+ count greater than 200/microliter* NOTE: *No restrictions if study vaccine administered at 6 months after transplantation Hepatic: - Bilirubin less than 2.0 mg/dL (unless due to lymphomatous involvement) - Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than 2 times normal (unless due to lymphomatous involvement) Renal: - Creatinine no greater than 2.0 mg/dL Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics Chemotherapy: - See Disease Characteristics Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified



Primary Contact:

Study Chair
Julie M. Vose, MD
University of Nebraska

Backup Contact:


Location Contact:

Omaha, Nebraska 68198
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.